NASDAQ·Biological Products, (No Diagnostic Substances)
KRYS
Krystal Biotech, Inc.
Krystal Biotech, Inc. (ticker: KRYS) is an NASDAQ-listed biological products, (no diagnostic substances) company. DredgeCap's structured extraction of KRYS's SEC filings surfaces 1 active risk signal, including 1 auditor-change signal. KRYS reported $116.36M in revenue and $55.93M for the period ending 2026-03-31, with operating cash flow of $80.38M. Cash and equivalents stood at $501.31M (up 62.4% year-over-year). Total assets of $1.40B exceed total liabilities of $120.24M. Each signal on this page is sourced verbatim from the underlying SEC filing. Use the tabs above to drill into auditor history, going-concern citations, dilution mechanics, cash runway, and the full risk-flag inventory.
KRYS SEC Filings
Full cached SEC EDGAR filing history for KRYS, grouped by form type and sorted newest-first within each group. 0 filings across 0 form types.
Filings sourced verbatim from SEC EDGAR submissions metadata. “Structured” links route to DredgeCap's per-filing renderer (XBRL-backed financials + cited highlights) when available; the EDGAR link always points to the canonical accession index on sec.gov.